Toxoid

LimmaTech Biologics Expands Vaccine Pipeline by Licensing AbVacc’s Innovative Vaccine Candidate Against Staphylococcus aureus

Retrieved on: 
Tuesday, December 19, 2023
Research, Infectious Diseases, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Rabbit, Infection, Multimedia, NIAID, Toxoid, Administration, Staphylococcus aureus, Mouse, Doctor of Philosophy, Recurrence, DHSC, Human services, REPAIR, Education, Bangladesh Technical Education Board, S. aureus, Staphylococcus, Patient, Development, BMBF, Social work, Skin, CARB-X, Vaccine

LimmaTech Biologics and AbVacc announced today a license agreement that grants LimmaTech the exclusive rights to further develop AbVacc’s multivalent toxoid vaccine candidate, LBT-SA7 (formerly IBT-V02), designed to prevent infections caused by the bacterial pathogen, Staphylococcus aureus (S. aureus).

Key Points: 
  • LimmaTech Biologics and AbVacc announced today a license agreement that grants LimmaTech the exclusive rights to further develop AbVacc’s multivalent toxoid vaccine candidate, LBT-SA7 (formerly IBT-V02), designed to prevent infections caused by the bacterial pathogen, Staphylococcus aureus (S. aureus).
  • LimmaTech also receives an exclusive option, executable post Phase 1 read-out, to acquire full rights to the program.
  • The vaccine candidate contains weakened forms of toxins, referred to as toxoids, that would normally be secreted by the pathogen to cause an infection.
  • Preclinical studies in mice and rabbits demonstrated strong neutralizing activity against several clinically relevant forms of S. aureus infection.

U.S. Army Validates SteraMist iHP Technology’s Efficacy on Various Biological Toxoids, Including Ricin

Retrieved on: 
Wednesday, May 31, 2023
Hydrogen, Toxoid, Partnership, DARPA, VHP, U.S. Department of Defense Strategy for Operating in Cyberspace, Decontamination, United States Department of Defense, Horsepower, BIT, Temperature, BSAT, History, Stainless steel, Sterilization, Ricin, School, Humidity, Hospital, Hydrogen peroxide, Restaurant, Police, Annual report, Disinfectant, Polycarbonate, Meat, Environmental remediation, Vaccine, Risk management

The study aimed to determine if biological toxins can be decontaminated by iHP at a shorter exposure time as compared to Vaporized Hydrogen Peroxide (VHP).

Key Points: 
  • The study aimed to determine if biological toxins can be decontaminated by iHP at a shorter exposure time as compared to Vaporized Hydrogen Peroxide (VHP).
  • "These results validate the significant potential of iHP as a powerful technology for decontaminating biological toxoids,” states Elissa J.
  • These forward-looking statements include, without limitation, statements relating to the potential of iHP technology and SteraMist’s opportunities in new partnerships.
  • As such, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors.

Veterinary Pain Management Market worth $2.5 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, September 22, 2022
Knowledge, Chanelle Pharma Novice Hurdle, GEM, Adoption, Temperature, Lists of diseases, Brain, Dechra Pharmaceuticals, Prevalence, Nonsteroidal anti-inflammatory drug, Poultry, Inactivation, Overweight, Merck & Co., Population, Osteoarthritis, USD, Cancer, Intelligence, Pain, Rabies, SME, Arthralgia, Tissue, Livestock, Research, Pain management, PETS, CAGR, Vaccine, Marketing, Aquaculture, Toxoid, Coccidiosis, Brucellosis, Technology, Disease

In this report, the veterinary pain management market has been segmented by product, application, animal type, end user, and region.

Key Points: 
  • In this report, the veterinary pain management market has been segmented by product, application, animal type, end user, and region.
  • In 2021, the NSAIDs segment accounted for largest share of the veterinary pain management drugs market.
  • The veterinary pain management drugs market is segment into oral, parenteral, and topical on the basis of route of administration.
  • Based on applications, the veterinary pain management market is segmented into joint pain, post-operative pain, cancer, and other applications.

TOMI Environmental Solutions, Inc. Reports First Quarter 2022 Financial Results

Retrieved on: 
Thursday, May 5, 2022
Hydrogen, FDIC International, Business, Three Months Gone, GAAP, Disinfectant, BIT, Tax, IHP, Infection, Annual report, SEC, Toxoid, Decontamination, SEB, Mycotoxin, Forward-looking statement, Mission statement, Adjustment, NASDAQ, RIA, Onboarding, Company, Partnership, American Association, ARM, Hospital, Ionization, Finance, Association, DARPA, Research, Operating cost, EBITDA, Omicron, Hydrogen peroxide, School, American Biological Safety Association, Servpro, Growth, Police, COVID-19, Public sector banks in India, Calendar, LLC, GLOBE, U.S. Department of Defense Strategy for Operating in Cyberspace, Â, Depreciation, Webcast, Investor relations, CES, Meat, Conference, Restaurant, Renewable energy, Video game, Airline, Bookkeeping, Commercial property, Uranium, Bank, Epidemiology

FREDERICK, Md., May 05, 2022 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (TOMI) (NASDAQ:TOMZ), a global company specializing in disinfection and decontamination utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist brand of products, today announced its financial results for the first quarter of 2022.

Key Points: 
  • FREDERICK, Md., May 05, 2022 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (TOMI) (NASDAQ:TOMZ), a global company specializing in disinfection and decontamination utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist brand of products, today announced its financial results for the first quarter of 2022.
  • We intend to build on our first quarter results to deliver continued improved financial results in 2022 and remain focused on growing our revenue, expanding our customer base, adding key employees and increasing our brand recognition in the marketplace, Dr. Shane concluded.
  • TOMI will hold a conference call to discuss First Quarter 2022 results at 4:30 p.m.
  • Investors are encouraged to review the related U.S. GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable U.S. GAAP financial measures.

Intravacc publishes positive phase I Shigella conjugate vaccine data

Retrieved on: 
Monday, November 16, 2020
Vaccines, Medical specialties, Medicine, Clinical medicine, Vaccine, Conjugate vaccine, Toxoid, Tetanus vaccine, COVID-19 vaccine, Hib vaccine

Intravacc developed a production process for this conjugate vaccine, manufactured the GMP batch and did stability testing and batch release.

Key Points: 
  • Intravacc developed a production process for this conjugate vaccine, manufactured the GMP batch and did stability testing and batch release.
  • Currently there is no vaccine available against Shigella.
  • This experimental Shigella vaccine (SF2a-TT15), developed by Institut Pasteur, is a conjugate vaccine consisting of a synthetic oligosaccharide chemically linked to tetanus toxoid.
  • Intravacc also has its own proprietary vaccine platform and established state-of-the-art research and production (GMP) facilities.

Intravacc publishes positive phase I Shigella conjugate vaccine data

Retrieved on: 
Monday, November 16, 2020
Vaccines, Medical specialties, Medicine, Clinical medicine, Vaccine, Conjugate vaccine, Toxoid, Tetanus vaccine, COVID-19 vaccine, Hib vaccine

Intravacc developed a production process for this conjugate vaccine, manufactured the GMP batch and did stability testing and batch release.

Key Points: 
  • Intravacc developed a production process for this conjugate vaccine, manufactured the GMP batch and did stability testing and batch release.
  • Currently there is no vaccine available against Shigella.
  • This experimental Shigella vaccine (SF2a-TT15), developed by Institut Pasteur, is a conjugate vaccine consisting of a synthetic oligosaccharide chemically linked to tetanus toxoid.
  • Intravacc also has its own proprietary vaccine platform and established state-of-the-art research and production (GMP) facilities.

Global Tetanus Toxoid Vaccine Market (2020 to 2025) - Growth, Trends, and Forecast - ResearchAndMarkets.com

Retrieved on: 
Friday, August 14, 2020
Infectious diseases, Pharmaceutical, Health, Medical specialties, Clinical medicine, Drugs, Vaccines, RTT, Tetanus, Toxoid, Vaccine, Diphtheria, Whooping cough, DTaP-Hib vaccine, DPT vaccine

Diphtheria, Tetanus, and Pertussis (DTaP) vaccines segment holds a significant market share in the tetanus toxoid vaccine market and is anticipated to show a similar trend over the forecast period owing to growing government initiatives to eradicate these diseases.

Key Points: 
  • Diphtheria, Tetanus, and Pertussis (DTaP) vaccines segment holds a significant market share in the tetanus toxoid vaccine market and is anticipated to show a similar trend over the forecast period owing to growing government initiatives to eradicate these diseases.
  • DTaP is a vaccine that helps in developing immunity against three deadly diseases caused by diphtheria, tetanus, and whooping cough (pertussis) in children younger than 7 years old.
  • According to the World Health Organization (WHO), in 2017 worldwide 38,000 people died from tetanus.
  • North America is expected to hold a major market share in the global tetanus toxoid vaccine market due to increasing cases of tetanus and diphtheria, and higher cost, high coverage, and adoption in this region.

Pfenex Reports Second Quarter 2020 Results and Provides Business Update

Retrieved on: 
Thursday, August 6, 2020
Medical specialties, Health, RTT, Vaccines, Adjuvants, CRM197, Teriparatide, Pharmaceutical industry, Vaccine, Diphtheria, Alvogen, Toxoid

The second quarter of 2020 marked a significant milestone for Pfenex as our partner, Alvogen, launched Teriparatide Injection in the U.S. in June.

Key Points: 
  • The second quarter of 2020 marked a significant milestone for Pfenex as our partner, Alvogen, launched Teriparatide Injection in the U.S. in June.
  • In June 2020, the Committee for Medicinal Products for Human Use of Medicines provided a positive opinion on PF708.
  • In August 2020, Pfenex and Merck signed a research and collaboration agreement to evaluate a specified set of proteins to be produced via the Pfenex Expression Technology platform.
  • Pfenex also uses its Pfenex Expression Technology platform to produce CRM197, a diphtheria toxoid carrier protein for use in prophylactic and therapeutic vaccines.

Pfenex to Announce Second Quarter Financial Results on August 6

Retrieved on: 
Monday, July 20, 2020
Medical specialties, RTT, Clinical medicine, Health, Adjuvants, CRM197, Vaccines, Vaccine, New York Stock Exchange, Diphtheria, Toxoid

SAN DIEGO, July 20, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that it will report its financial results for the second quarter ended June 30, 2020, after the market close on Thursday, August 6, 2020.

Key Points: 
  • SAN DIEGO, July 20, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that it will report its financial results for the second quarter ended June 30, 2020, after the market close on Thursday, August 6, 2020.
  • Pfenex will host a conference call and webcast to discuss its financial results and provide a company update that day at 1:30 PM Pacific Time (4:30 PM Eastern Time).
  • Pfenex also uses its Pfenex Expression Technology platform to produce CRM197, a diphtheria toxoid carrier protein for use in prophylactic and therapeutic vaccines.
  • Pfenex encourages its investors and others to monitor and review the information Pfenex makes public in these locations as such information could be deemed to be material information.

MenQuadfi (Quadrivalent Polysaccharide Tetanus Toxoid Conjugate Vaccine) Drug Overview

Retrieved on: 
Monday, June 15, 2020
Medical specialties, Bacteria, Vaccines, Medicine, RTT, Conjugate vaccine, Bacterial diseases, Vaccine-preventable diseases, Neisseria meningitidis, Vaccine, Tetanus, Toxoid

DUBLIN, June 15, 2020 /PRNewswire/ -- The "MenQuadfi (quadrivalent polysaccharide tetanus toxoid conjugate vaccine) Drug Overview" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, June 15, 2020 /PRNewswire/ -- The "MenQuadfi (quadrivalent polysaccharide tetanus toxoid conjugate vaccine) Drug Overview" report has been added to ResearchAndMarkets.com's offering.
  • Sanofi's MenQuadfi (quadrivalent polysaccharide tetanus toxoid conjugate vaccine) is a second-generation active polyvalent conjugate vaccine against group A, C, Y, and W meningococcal infection.
  • It is presented as a sterile solution for injection containing Neisseria meningitidis capsular polysaccharide antigens individually conjugated to tetanus toxoid protein.
  • Sanofi has submitted a Biologics License Application (BLA) for MenQuadfi to the US Food and Drug Administration (FDA) with a target action date of April 2020.